|
Written by Janus
|
|
Tuesday, 05 March 2013 14:46 |
|
Varstiff technology, developed at the Tecnalia technological center, from the Basque Country, allows generating adaptable rigid structures from flexible textile material, with numerous applications in health, entertainment, and sports or automotive.
Its use is intended for emergency and healthcare applications in orthopedics, and, thanks to the cooperation agreement reached between the three parties under the name Refit it has been one of the three awarded projects of the first edition of the Mind the Gap program from the Fundación Botín.
The financial support of the Fundacion Botin and FIK, along with the work of the staff from Janus and Tecnalia, will allow to complete the development of two products and to create a new company to commercialize the technology worldwide.
http://www.youtube.com/watch?v=81am7XDy0WQ
|
|
Read more...
|
|
|
Written by Janus
|
|
Friday, 01 February 2013 14:08 |
|
After a long history of collaboration between three research groups at the UB, the CSIC and the UAB in the investigation of nucleic acids interference (siRNA), have found the solution in inhibiting , among others, genes involved in inflammatory diseases, such as those related to the action of Tumor Necrosis Factor (TNF-alpha). As a result of this project in 2010 applied for a patent that has been recently licensed to the company Janus Developments Ltd.
The results obtained so far do predict that in the long term these products could be useful in the treatment of inflammatory diseases such as Crohn's disease, ulcerative colitis, asthma, psoriasis and even some types of cancer diseases. The regulation of this factor could allow a considerable improvement if patients eventually may apply, after clinical development.
|
|
|
Written by Janus
|
|
Wednesday, 16 January 2013 09:53 |
|
A growing number of insights on the biology of bacterial inclusion bodies (IBs) have revealed intriguing utilities of these protein particles. Since they combine mechanical stability and protein functionality, IBs have been already exploited in biocatalysis and explored for bottom-up topographical modification in tissue engineering. Being fully biocompatible and with tuneable bio-physical properties, IBs are currently emerging as agents for protein delivery into mammalian cells in protein-replacement cell therapies. So far, IBs formed by chaperones (heat shock protein 70, Hsp70), enzymes (catalase and dihydrofolate reductase), grow factors (leukemia inhibitory factor, LIF) and structural proteins (the cytoskeleton keratin 14) have been shown to rescue exposed cells from a spectrum of stresses and restore cell functions in absence of cytotoxicity. The natural penetrability of IBs into mammalian cells (reaching both cytoplasm and nucleus) empowers them as an unexpected platform for the controlled delivery of essentially any therapeutic polypeptide. Production of protein drugs by biopharma has been traditionally challenged by IB formation. However, a time might have arrived in which recombinant bacteria are to be engineered for the controlled packaging of therapeutic proteins as nanoparticulate materials (nanopills), for their extra- or intra-cellular release in medicine and cosmetics.
http://www.microbialcellfactories.com/content/11/1/76
|
|
